Table 1.
Baseline characteristics of the Canary Prostate Active Surveillance Study sub-cohort stratified by interval (tertiles) from diagnostic biopsy to first active surveillance (AS) biopsy
| Subgroup (N) | <8 months 119 (28.3%) |
8–13 months 173 (41.1%) |
>13 months 129 (30.6%) |
P-value1 | |
|---|---|---|---|---|---|
| Outcome | |||||
| Reclassified on2 First AS biopsy | Gleason (77) | 25 (21.0) | 25 (14.5) | 27 (20.9) | 0.29 |
| Volume (34) | 7 (5.9) | 15 (8.7) | 12 (9.3) | 0.58 | |
| Either (89) | 28 (23.5) | 33 (19.2) | 28 (21.7) | 0.71 | |
| Demographics | |||||
| Age at diagnosis | <55 (61) | 15 (12.6) | 26 (15.0) | 20 (15.5) | 0.43 |
| 55–64.9 (190) | 53 (44.5) | 86 (49.7) | 51 (39.5) | ||
| ≥65 (170) | 51 (42.9) | 61 (35.3) | 58 (45.0) | ||
| Race | White (382) | 106 (89.1) | 157 (90.8) | 119 (92.3) | 0.49 |
| Black (19) | 8 (6.7) | 5 (2.9) | 6 (4.6) | ||
| Other (20) | 5 (4.2) | 11 (6.3) | 4 (3.1) | ||
| Ethnicity | Hispanic (17) | 2 (1.7) | 6 (3.5) | 9 (7.0) | 0.09 |
| Non-Hispanic (404) | 117 (98.3) | 167 (96.5) | 120 (93.0) | ||
| Clinical factors | |||||
| Family history | Positive (103) | 35 (29.4) | 43 (24.8) | 25 (19.4) | 0.42 |
| Negative (300) | 79 (66.4) | 124 (71.7) | 97 (75.2) | ||
| Missing (18) | 5 (4.2) | 6 (3.5) | 7 (5.4) | ||
| Body Mass Index (kg/m2) | <25 (100) | 25 (21.0) | 49 (28.3) | 26 (20.2) | 0.18 |
| 25–29.9 (215) | 60 (50.4) | 88 (50.9) | 67 (51.9) | ||
| 30–34.9 (71) | 26 (21.9) | 25 (14.4) | 20 (15.5) | ||
| ≥35 (35) | 8 (6.7) | 11 (6.4) | 16 (12.4) | ||
| Cancer and biopsy-related covariates | |||||
| PSA (ng/ml) | <4 (125) | 29 (24.4) | 58 (33.5) | 38 (29.4) | 0.26 |
| 4–10 (270) | 79 (66.4) | 105 (60.7) | 86 (66.7) | ||
| 10–20 (37) | 11 (9.2) | 10 (5.8) | 5 (3.9) | ||
| PSA Density (ng) | <0.15 (291) | 77 (64.7) | 119 (68.8) | 95 (73.6) | 0.31 |
| ≥0.15 (130) | 42 (35.3) | 54 (31.2) | 34 (26.3) | ||
| Digital Rectal Exam4 | Benign (358) | 106 (90.6) | 139 (83.7)3 | 113 (89.0) | 0.18 |
| Suspicious (52) | 11 (9.4) | 27 (16.3) | 14 (11.0) | ||
| NCCN | Low/Very Low (395) | 108 (90.8) | 163 (94.2) | 124 (96.1) | 0.20 |
| Intermediate (26) | 11 (9.2) | 10 (5.8) | 5 (3.9) | ||
| Cancer of the Prostate Risk Assessment Score (CAPRA)3 | 0 (19) | 4 (3.4) | 7 (4.0) | 8 (6.2) | 0.61 |
| 1 (291) | 78 (65.5) | 124 (71.7) | 89 (69.0) | ||
| 2 (87) | 27 (22.7) | 33 (19.1) | 27 (20.9) | ||
| 3 (24) | 10 (8.4) | 9 (5.2) | 5 (3.9) | ||
| Prostate Volume by TRUS (cm3) | <30 (112) | 23 (19.3) | 50 (28.9) | 39 (30.2) | 0.16 |
| 30–50 (171) | 56 (47.1) | 71 (41.0) | 44 (34.1) | ||
| >50 (138) | 40 (33.6) | 52 (30.1) | 46 (35.7) | ||
| Location diagnostic biopsy | Study Center (162) | 31 (26.1) | 82 (47.4) | 49 (38.0) | <0.01 |
| Off site (259) | 88 (73.9) | 91 (53.6) | 80 (62.0) | ||
1
Chi-squared tests.
2
N (% of cohort with first AS biopsy in that time period)
3
No CAPRA >3 in cohort.
4
Missing data on 10 men.